Lisa Lancaster
Endeavor Biomedicines · Vanderbilt University Medical Center · Vanderbilt University, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lisa Lancaster as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:59 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07454291 · A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy ParticipantsEndeavor Biomedicines, Inc. · recruiting · Idiopathic Pulmonary Fibrosis · study director
- Ph2NCT06422884 · A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Endeavor Biomedicines, Inc. · active not recruiting · Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease · study director
- Ph2NCT05199584 · A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc. · completed · Solid Tumors With PTCH1 Loss-of-function Mutations · study director
- N/ANCT03562247 · Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)Vanderbilt University Medical Center · terminated · Idiopathic Pulmonary Fibrosis · principal investigator
- Ph2NCT01890265 · Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)Kyntra Bio · completed · Idiopathic Pulmonary Fibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- OBSTRUCTIVE SLEEP APNEA IN IPFM01RR000095 · NCRR · VANDERBILT UNIVERSITY · fiscal years 2007 to 2008 · $105 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:59 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- 3,203 citationsRCR 107.5
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet · 20111,701 citationsRCR 48.7
- 427 citationsRCR 10.7
- BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med · 2008423 citationsRCR 11.8
- Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.Am J Respir Crit Care Med · 2011372 citationsRCR 13.1
- 208 citationsRCR 8.1
- FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.Eur Respir J · 2016141 citationsRCR 5.3
- 141 citationsRCR 6.0
- Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.Eur Respir J · 2016131 citationsRCR 5.5
- CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.Eur Respir J · 2015127 citationsRCR 4.0